Sümeyye Aksoy
Research Subjects
Research Interests
Sümeyye Aksoy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Birkan Yakan
Erciyes Universitesi
2 shared publications - Derya Karabulut
Department of Histology-Embryology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Nurhan Kuloğlu
Niğde Ömer Halisdemir Üniversitesi
2 shared publications - Cevat Yazici
Department of Biochemistry, Faculty of Medicine, Erciyes University, Kayseri, Turkey
1 shared publication - Inayet Gunturk
Department of Midwifery, Faculty of Health Sciences, Nigde Omer Halisdemir University, Nigde Zubeyde Hanım, Nigde
1 shared publication - Necla Değer
Department of Histology‐Embryology, Faculty of Medicine Erciyes University Kayseri Turkey
1 shared publication
Latest Publications
- Open Access
- 7 April 2025
- Published by Erciyes Universitesi (DergiPark) in Sağlık Bilimleri Dergisi
- Vol. 34 (1) , 1-7
MYRICETIN REDUCES CISPLATIN-INDUCED LUNG INJURY BY REGULATING OXIDATIVE STRESS AND HYPOXIA INDUCIBLE FACTOR-1α LEVELS
Cisplatin is an anticancer agent that is frequently used in the treatment of solid tumors. However, widespread organ toxicity is the most important factor limiting its use. Lung toxicity has also become an increasing concern in recent years. This study aimed to evaluate the protective roles of myricetin, a natural antioxidant found in plants, in cisplatin-induced lung injury. For this purpose, twenty-eight male Wistar rats were randomly assigned to four equal groups (n=7): control, myricetin, cisplatin, and myricetin+cisplatin. The control group received physiological saline; the myricetin group was given myricetin (10 mg/kg) intraperitoneally for seven consecutive days. The cisplatin group was given a single dose of cisplatin (7.5 mg/kg) intraperitoneally on the seventh day. The myricetin+cisplatin group was treated with myricetin for seven consecutive days, and at the end of the seventh day, cisplatin was administered. One day later, the rats were sacrificed, and their lungs were removed. The sections obtained from the lungs were stained with hematoxylin & eosin, and histopathological damage was evaluated. Biochemical analyses were performed using total oxidant status, total antioxidant status, and hypoxia-inducible factor-1α. In results, significant inflammatory cell infiltration, cellular deterioration, and loss of tissue integrity were observed in the cisplatin group. In contrast, in the myricetin+cisplatin group, the cellular structure and alveolar order were largely preserved, and inflammatory infiltration was minimal. Pretreatment with myricetin reduced total oxidant status and hypoxia-inducible factor-1α while increasing total antioxidant status levels. Taken together, this study indicates that pretreatment of myricetin could serve therapeutic purposes in cisplatin-induced lung injury.
- 7 April 2025
- Published by Erciyes Universitesi (DergiPark) in Sağlık Bilimleri Dergisi
- Vol. 34 (1) , 1-7
Open AccessMYRICETIN REDUCES CISPLATIN-INDUCED LUNG INJURY BY REGULATING OXIDATIVE STRESS AND HYPOXIA INDUCIBLE FACTOR-1α LEVELS
Cisplatin is an anticancer agent that is frequently used in the treatment of solid tumors. However, widespread organ toxicity is the most important factor limiting its use. Lung toxicity has also become an increasing concern in recent years. This study aimed to evaluate the protective roles of myricetin, a natural antioxidant found in plants, in cisplatin-induced lung injury. For this purpose, twenty-eight male Wistar rats were randomly assigned to four equal groups (n=7): control, myricetin, cisplatin, and myricetin+cisplatin. The control group received physiological saline; the myricetin group was given myricetin (10 mg/kg) intraperitoneally for seven consecutive days. The cisplatin group was given a single dose of cisplatin (7.5 mg/kg) intraperitoneally on the seventh day. The myricetin+cisplatin group was treated with myricetin for seven consecutive days, and at the end of the seventh day, cisplatin was administered. One day later, the rats were sacrificed, and their lungs were removed. The sections obtained from the lungs were stained with hematoxylin & eosin, and histopathological damage was evaluated. Biochemical analyses were performed using total oxidant status, total antioxidant status, and hypoxia-inducible factor-1α. In results, significant inflammatory cell infiltration, cellular deterioration, and loss of tissue integrity were observed in the cisplatin group. In contrast, in the myricetin+cisplatin group, the cellular structure and alveolar order were largely preserved, and inflammatory infiltration was minimal. Pretreatment with myricetin reduced total oxidant status and hypoxia-inducible factor-1α while increasing total antioxidant status levels. Taken together, this study indicates that pretreatment of myricetin could serve therapeutic purposes in cisplatin-induced lung injury.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (7) , e20240136
Investigation of the effect of Myricetin on Cisplatin-induced liver hepatotoxicity
Cisplatin, a widely used anticancer agent, induces hepatotoxicity alongside organ damage. Understanding Cisplatin's toxicity mechanism and developing preventive measures are crucial. Our study explores Myricetin, a flavonoid, for its protective effects against Cisplatin-induced hepatotoxicity.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 70 (7) , e20240136
Open AccessInvestigation of the effect of Myricetin on Cisplatin-induced liver hepatotoxicity
Cisplatin, a widely used anticancer agent, induces hepatotoxicity alongside organ damage. Understanding Cisplatin's toxicity mechanism and developing preventive measures are crucial. Our study explores Myricetin, a flavonoid, for its protective effects against Cisplatin-induced hepatotoxicity.